<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Life Sciences</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9E2C184C-9DFE-4F33-9F17-F63C058B2F68"><gtr:id>9E2C184C-9DFE-4F33-9F17-F63C058B2F68</gtr:id><gtr:firstName>Rudiger</gtr:firstName><gtr:surname>Woscholski</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0000138"><gtr:id>7EF1BF90-1BC0-4CE2-B493-1580B3473184</gtr:id><gtr:title>Functional analysis of type II phosphoinositide 5-phosphatases</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0000138</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-05-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>436437</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK (CRUK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>London Research Institute (LRI)</gtr:department><gtr:description>Lipid signaling</gtr:description><gtr:id>674E575C-9507-4BA0-B876-04C8C6285FA9</gtr:id><gtr:impact>The collaboration resulted in a few papers: 16942862: 17030795: 19165341.</gtr:impact><gtr:partnerContribution>Joint studentships and projects.</gtr:partnerContribution><gtr:piContribution>Provided advice, manpower, tools and techniques.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>fundraising with charity</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1BC12D0A-71C2-43CF-8632-1D234B137F36</gtr:id><gtr:impact>Attended fundraising even for Lowe syndrome Trust where I answered question about our research to the public.

Our research was funded by the Lowe Syndrome Trust.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>79000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Lowe Syndrome Trust UK studentship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Lowe Syndrome Trust</gtr:fundingOrg><gtr:id>BBE4097A-CA61-423D-98A7-AA7520822568</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>188000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Programme Grant</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>6BA986CD-4D9A-44D9-8DFF-BC41CC70DEFF</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>34000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leverhulme Trust Project Grant</gtr:description><gtr:end>2009-10-02</gtr:end><gtr:fundingOrg>The Leverhulme Trust</gtr:fundingOrg><gtr:id>8A05780E-2153-4302-A3B2-791EA1E88115</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Small molecule inhibitor selective for the phosphatase PTEN.</gtr:description><gtr:id>3793FC50-5D96-42E7-AC4D-CF4DD89061B5</gtr:id><gtr:impact>see research tools section</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>US2007292532</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>PTEN inhibitor</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chemical Biology text book</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>659ADDC0-AF4A-4D71-9F65-7BA9D2C99FA9</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BBSRC advisory board</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6677E846-1D60-43BE-92EF-2706972E7169</gtr:id><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRes in Chemical Biology</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>F408417A-8EC6-4D90-8AE5-213D2DCD31D2</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>see research tools and intellectual property section.</gtr:description><gtr:id>AD4A9EA6-C326-4833-9766-1AD3FF5E761B</gtr:id><gtr:impact>see research tools and intellectual property section.</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PTEN inhibitor</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A novel high affinity small molecule inhibitor specific for the tumour suppressor PTEN has been developed and protected.</gtr:description><gtr:id>5E2B75BD-0DE1-4628-8366-B92838DFB3AC</gtr:id><gtr:impact>Manuscripts are currently under review for some collaborations where material has been provided. Compound has been used by Prof. Van Haesebroeck to validate feedback between PI 3-kinase and PTEN. Compound is now under license with a small company in the US.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PTEN inhibitor</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/95D9BA97-DE70-4478-9B8D-3FD8FF6ADCDC"><gtr:id>95D9BA97-DE70-4478-9B8D-3FD8FF6ADCDC</gtr:id><gtr:title>Spatial localization of PtdInsP2 in phase-separated giant unilamellar vesicles with a fluorescent PLC-delta 1 PH domain.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b5e7fc03a95776f7781f6f33c7c7d13"><gtr:id>1b5e7fc03a95776f7781f6f33c7c7d13</gtr:id><gtr:otherNames>Mulet X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EA809995-00D0-4DF4-B214-24ADD6BFA96A"><gtr:id>EA809995-00D0-4DF4-B214-24ADD6BFA96A</gtr:id><gtr:title>The novel molecule 2-[5-(2-chloroethyl)-2-acetoxy-benzyl]-4-(2-chloroethyl)-phenyl acetate inhibits phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signalling through JNK activation in cancer cells.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b0cd06eff3f05d46bc21d2e8e16f7aab"><gtr:id>b0cd06eff3f05d46bc21d2e8e16f7aab</gtr:id><gtr:otherNames>Ho KK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E2788573-B598-48C0-907F-58282BE611ED"><gtr:id>E2788573-B598-48C0-907F-58282BE611ED</gtr:id><gtr:title>Specific N-terminal protein labelling: use of FMDV 3C pro protease and native chemical ligation.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a05f0f6d021efeac9dbf7a1bae33662e"><gtr:id>a05f0f6d021efeac9dbf7a1bae33662e</gtr:id><gtr:otherNames>Busch GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/40C4D53C-191D-4891-AFF8-901A0279FE8D"><gtr:id>40C4D53C-191D-4891-AFF8-901A0279FE8D</gtr:id><gtr:title>Differential activation of the PI 3-kinase effectors AKT/PKB and p70 S6 kinase by compound 48/80 is mediated by PKCalpha.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f754ca37107eea521b909fe2d2aab42e"><gtr:id>f754ca37107eea521b909fe2d2aab42e</gtr:id><gtr:otherNames>Byrne RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4B5D3B64-1C10-4874-B997-33E4D7AEF586"><gtr:id>4B5D3B64-1C10-4874-B997-33E4D7AEF586</gtr:id><gtr:title>A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN).</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a94ea778e8484b04439e7a5cdf1c18f1"><gtr:id>a94ea778e8484b04439e7a5cdf1c18f1</gtr:id><gtr:otherNames>Rosivatz E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/43011A38-1E17-463C-9E22-5B8A4F21E205"><gtr:id>43011A38-1E17-463C-9E22-5B8A4F21E205</gtr:id><gtr:title>Measurement of PTEN activity in vivo by imaging phosphorylated Akt.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a94ea778e8484b04439e7a5cdf1c18f1"><gtr:id>a94ea778e8484b04439e7a5cdf1c18f1</gtr:id><gtr:otherNames>Rosivatz E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/138F031D-272C-4073-9CE8-8E29D26339A4"><gtr:id>138F031D-272C-4073-9CE8-8E29D26339A4</gtr:id><gtr:title>Evidence that phosphatidylinositol promotes curved membrane interfaces.</gtr:title><gtr:parentPublicationTitle>Langmuir : the ACS journal of surfaces and colloids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b5e7fc03a95776f7781f6f33c7c7d13"><gtr:id>1b5e7fc03a95776f7781f6f33c7c7d13</gtr:id><gtr:otherNames>Mulet X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0743-7463</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/50B30239-3B5D-4C3B-9492-0713FE5863B6"><gtr:id>50B30239-3B5D-4C3B-9492-0713FE5863B6</gtr:id><gtr:title>Identification of cyclin A2 as the downstream effector of the nuclear phosphatidylinositol 4,5-bisphosphate signaling network.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b0cd06eff3f05d46bc21d2e8e16f7aab"><gtr:id>b0cd06eff3f05d46bc21d2e8e16f7aab</gtr:id><gtr:otherNames>Ho KK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C4212A3C-6AA9-4335-9800-0AD192234A3D"><gtr:id>C4212A3C-6AA9-4335-9800-0AD192234A3D</gtr:id><gtr:title>Nuclear envelope remnants: fluid membranes enriched in sterols and polyphosphoinositides.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0b61f9e7069b4e11b10ff2e5b0d0ce58"><gtr:id>0b61f9e7069b4e11b10ff2e5b0d0ce58</gtr:id><gtr:otherNames>Garnier-Lhomme M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ED491D61-20C1-4BAE-B0EA-7E4A4FF3ED6B"><gtr:id>ED491D61-20C1-4BAE-B0EA-7E4A4FF3ED6B</gtr:id><gtr:title>Compartmental signal modulation: Endosomal phosphatidylinositol 3-phosphate controls endosome morphology and selective cargo sorting.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ae30933c3da9fccfd5cdbdd4c169d63b"><gtr:id>ae30933c3da9fccfd5cdbdd4c169d63b</gtr:id><gtr:otherNames>Fili N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0000138</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>